Literature DB >> 21160804

Strategies for gastric cancer in the modern era.

Satoru Takayama1, Takehiro Wakasugi, Hitoshi Funahashi, Hiromitsu Takeyama.   

Abstract

Gastric cancer is one of the most common neoplasms in Japan, and it is also the second leading cause of cancer-related deaths worldwide. Nowadays, infection with Helicobacter pylori (H. pylori) is a known risk factor for the development of gastric cancer. Therefore, gastric cancer should be considered as an infectious disease, and in fact, prophylactic eradication of H. pylori may prevent the development of metachronous gastric carcinoma. Before the role of H. pylori was understood, a different approach was used. Recently even after the cancer has developed, some newer therapeutic approaches have been pursued. These newer treatments have been summarized as "minimally invasive therapies" and use endoscopic or laparoscopic techniques. In addition, robotic approaches are being developed that seem to hold a great potential to change the surgical approach. Since basic understanding and treatment of the disease have both changed significantly over the last decade, we present a review of current advances in gastric cancer research and therapy.

Entities:  

Keywords:  Endoscopic submucosal dissection; Gastric cancer; Helicobacter pylori; Laparoscopy-assisted distal gastrectomy; Robot

Year:  2010        PMID: 21160804      PMCID: PMC2999138          DOI: 10.4251/wjgo.v2.i9.335

Source DB:  PubMed          Journal:  World J Gastrointest Oncol


  51 in total

1.  Re: Helicobacter pylori seropositivity as a risk factor for pancreatic cancer.

Authors:  Hans-Olof Nilsson; Unne Stenram; Ingemar Ihse; Torkel Wadström
Journal:  J Natl Cancer Inst       Date:  2002-04-17       Impact factor: 13.506

2.  Complete endoscopic closure of gastric perforation induced by endoscopic resection of early gastric cancer using endoclips can prevent surgery (with video).

Authors:  Shinya Minami; Takuji Gotoda; Hiroyuki Ono; Ichiro Oda; Hisanao Hamanaka
Journal:  Gastrointest Endosc       Date:  2006-04       Impact factor: 9.427

3.  Prospective randomized study of open versus laparoscopy-assisted distal gastrectomy with extraperigastric lymph node dissection for early gastric cancer.

Authors:  H Hayashi; T Ochiai; H Shimada; Y Gunji
Journal:  Surg Endosc       Date:  2005-07-28       Impact factor: 4.584

4.  Lymphadenectomy for cure in patients with early gastric cancer and lymph node metastasis.

Authors:  T Okamura; S Tsujitani; D Korenaga; M Haraguchi; H Baba; Y Hiramoto; K Sugimachi
Journal:  Am J Surg       Date:  1988-03       Impact factor: 2.565

5.  Helicobacter pylori infection and gastric histology in first-degree relatives of gastric cancer patients: a meta-analysis.

Authors:  Theodore Rokkas; Panos Sechopoulos; Dimitrios Pistiolas; Georgios Margantinis; Georgios Koukoulis
Journal:  Eur J Gastroenterol Hepatol       Date:  2010-09       Impact factor: 2.566

6.  Outcomes and survival after laparoscopic gastrectomy for adenocarcinoma. Analysis on 65 patients operated on by conventional or robot-assisted minimal access procedures.

Authors:  R Pugliese; D Maggioni; F Sansonna; G C Ferrari; A Forgione; A Costanzi; C Magistro; J Pauna; S Di Lernia; D Citterio; C Brambilla
Journal:  Eur J Surg Oncol       Date:  2008-03-14       Impact factor: 4.424

Review 7.  Helicobacter pylori and gastric carcinogenesis.

Authors:  Masanori Hatakeyama
Journal:  J Gastroenterol       Date:  2009-03-07       Impact factor: 7.527

Review 8.  Oncogenic mechanisms of the Helicobacter pylori CagA protein.

Authors:  Masanori Hatakeyama
Journal:  Nat Rev Cancer       Date:  2004-09       Impact factor: 60.716

Review 9.  Trastuzumab for gastric cancer.

Authors:  Judith Meza-Junco; Heather-Jane Au; Michael B Sawyer
Journal:  Expert Opin Biol Ther       Date:  2009-12       Impact factor: 4.388

10.  Early gastric cancer: 46 cases treated in one surgical department.

Authors:  H M Sue-Ling; I Martin; J Griffith; D C Ward; P Quirke; M F Dixon; A T Axon; M J McMahon; D Johnston
Journal:  Gut       Date:  1992-10       Impact factor: 23.059

View more
  8 in total

Review 1.  Helicobacter pylori in First Nations and recent immigrant populations in Canada.

Authors:  Nicola Jones; Naoki Chiba; Carlo Fallone; Alan Thompson; Richard Hunt; Kevan Jacobson; Karen Goodman
Journal:  Can J Gastroenterol       Date:  2012-02       Impact factor: 3.522

2.  Proteomic analysis of gastric cancer and immunoblot validation of potential biomarkers.

Authors:  Nina Kočevar; Federico Odreman; Alessandro Vindigni; Snježana Frković Grazio; Radovan Komel
Journal:  World J Gastroenterol       Date:  2012-03-21       Impact factor: 5.742

Review 3.  Gastric infection by Helicobacter pylori.

Authors:  George Sachs; David R Scott; Yi Wen
Journal:  Curr Gastroenterol Rep       Date:  2011-12

4.  Targeted treatment of liver metastasis from gastric cancer using specific binding peptide.

Authors:  Jianfeng Gong; Gewen Tan; Nengquan Sheng; Weiqiang You; Zhigang Wang
Journal:  Am J Transl Res       Date:  2016-05-15       Impact factor: 4.060

5.  7-difluoromethoxyl-5,4'-di-n-octylgenistein inhibits growth of gastric cancer cells through downregulating forkhead box M1.

Authors:  Hong-Lin Xiang; Fei Liu; Mei-Fang Quan; Jian-Guo Cao; Yuan Lv
Journal:  World J Gastroenterol       Date:  2012-09-07       Impact factor: 5.742

6.  The role of laparoscopic surgery in gastric cancer.

Authors:  Theodoros E Pavlidis; Efstathios T Pavlidis; Athanasios K Sakantamis
Journal:  J Minim Access Surg       Date:  2012-04       Impact factor: 1.407

7.  Suppression of midkine gene promotes the antitumoral effect of cisplatin on human gastric cancer cell line AGS in vitro and in vivo via the modulation of Notch signaling pathway.

Authors:  Wenyan Tian; Jiaqing Shen; Weichang Chen
Journal:  Oncol Rep       Date:  2017-06-22       Impact factor: 3.906

8.  Combinatorial Antitumor Activity of Oxaliplatin with Epigenetic Modifying Agents, 5-Aza-CdR and FK228, in Human Gastric Cancer Cells.

Authors:  Jong Kook Park; Jung Seon Seo; Suk Kyeong Lee; Kenneth K Chan; Hyo-Jeong Kuh
Journal:  Biomol Ther (Seoul)       Date:  2018-11-01       Impact factor: 4.634

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.